← Leaderboards
Ethel Cesarman
Weill Medical Coll Of Cornell Univ
$22,572,616
Attributed
$33,100,202
Total exposure
17
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.3M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$33,100,202 · 17
By mechanism
R01$20,217,317 · 7
U01$5,785,729 · 2
T32$2,906,491 · 3
R25$2,071,816 · 1
R38$1,346,691 · 1
R21$764,158 · 2
Top collaborators
- Douglas F Nixon6 shared
- David Erickson5 shared
- Benjamin Elison Gewurz5 shared
- Jeffrey N Martin5 shared
- Aggrey Semwendero Semeere5 shared
- Yazmin Paulina Carrasco4 shared
- Lisa Giulino Roth4 shared
- Charles David Allis3 shared
Most similar at Weill Medical Coll Of Cornell Univ
Same institution · by research overlap
- Lisa Giulino Roth$4,411,176
- Steven Zvi Josefowicz$9,023,527
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorGenesCellsMalignant NeoplasmsB-LymphocytesInfectionPathogenesisLymphomaProteinsHuman Herpesvirus 8VirusAcquired Immunodeficiency SyndromeMediatingNeoplastic CellKaposi SarcomaGene ExpressionViralIn VitroMolecularLymphomagenesisAffectLeadTumorigenesisSignal Transduction
Grant awards (78)
Regulatory Crosstalk Between Human Endogenous Retroviruses, HIV, and EBV, in Lymphoma$1,064,245
R01 · FY2025 · CA
B cell determinants of EBV latency$827,246
U01 · FY2025 · CA · contact PI
Tri-I Stimulating Access to Research in Residency program (Tri-I StARR - NIAID)$448,897
R38 · FY2025 · AI
Rapid Sample-to-Answer Diagnosis of Kaposi's Sarcoma Across Sub-Saharan Africa using KS-COMPLETE$417,866
U01 · FY2025 · CA
Next-Gen Oncopathology Program$227,671
T32 · FY2025 · CA · contact PI
Rapid Sample-to-Answer Diagnosis of Kaposi's Sarcoma Across Sub-Saharan Africa using KS-COMPLETE$147,547
U01 · FY2025 · CA
Regulatory Crosstalk Between Human Endogenous Retroviruses, HIV, and EBV, in Lymphoma$108,000
R01 · FY2025 · CA
B cell determinants of EBV latency (supplement)$30,119
U01 · FY2025 · CA · contact PI
Regulatory Crosstalk Between Human Endogenous Retroviruses, HIV, and EBV, in Lymphoma$1,116,963
R01 · FY2024 · CA
B cell determinants of EBV latency$827,278
U01 · FY2024 · CA · contact PI
Rapid Sample-to-Answer Diagnosis of Kaposi's Sarcoma Across Sub-Saharan Africa using KS-COMPLETE$573,896
U01 · FY2024 · CA
Tri-I Stimulating Access to Research in Residency program (Tri-I StARR - NIAID)$448,897
R38 · FY2024 · AI
(PQ 6) New Models of KSHV Oncogenesis and KS Immune Environment$416,939
R01 · FY2024 · CA · contact PI
Next-Gen Oncopathology Program$354,055
T32 · FY2024 · CA · contact PI
(PQ 6) New Models of KSHV Oncogenesis and KS Immune Environment$241,538
R01 · FY2024 · CA · contact PI
Weill Cornell Initiative for Maximizing Student Development$229,896
T32 · FY2024 · GM
Regulatory Crosstalk Between Human Endogenous Retroviruses, HIV, and EBV, in Lymphoma$1,178,126
R01 · FY2023 · CA
B cell determinants of EBV latency$827,799
U01 · FY2023 · CA · contact PI
Role of novel onco-histone mutations in B-cell malignancies$651,559
R01 · FY2023 · CA · contact PI
Rapid Sample-to-Answer Diagnosis of Kaposi's Sarcoma Across Sub-Saharan Africa using KS-COMPLETE$612,608
U01 · FY2023 · CA
Weill Cornell Initiative for Maximizing Student Development$517,954
R25 · FY2023 · GM
Tri-I Stimulating Access to Research in Residency program (Tri-I StARR - NIAID)$448,897
R38 · FY2023 · AI
(PQ 6) New Models of KSHV Oncogenesis and KS Immune Environment$416,939
R01 · FY2023 · CA · contact PI
Next-Gen Oncopathology Program$361,841
T32 · FY2023 · CA · contact PI
(PQ 6) New Models of KSHV Oncogenesis and KS Immune Environment$238,995
R01 · FY2023 · CA · contact PI
Regulatory Crosstalk Between Human Endogenous Retroviruses, HIV, and EBV, in Lymphoma$1,178,618
R01 · FY2022 · CA
B cell determinants of EBV latency$864,001
U01 · FY2022 · CA · contact PI
Rapid Sample-to-Answer Diagnosis of Kaposi's Sarcoma Across Sub-Saharan Africa using KS-COMPLETE$657,369
U01 · FY2022 · CA
Role of novel onco-histone mutations in B-cell malignancies$651,559
R01 · FY2022 · CA · contact PI
Weill Cornell Initiative for Maximizing Student Development$517,954
R25 · FY2022 · GM
(PQ 6) New Models of KSHV Oncogenesis and KS Immune Environment$416,939
R01 · FY2022 · CA · contact PI
(PQ 6) New Models of KSHV Oncogenesis and KS Immune Environment$238,995
R01 · FY2022 · CA · contact PI
Next-Gen Oncopathology Program$173,797
T32 · FY2022 · CA · contact PI
Regulatory Crosstalk Between Human Endogenous Retroviruses, HIV, and EBV, in Lymphoma$1,200,301
R01 · FY2021 · CA
Role of novel onco-histone mutations in B-cell malignancies$664,854
R01 · FY2021 · CA · contact PI
Weill Cornell Initiative for Maximizing Student Development$517,954
R25 · FY2021 · GM · contact PI
(PQ 6) New Models of KSHV Oncogenesis and KS Immune Environment$416,939
R01 · FY2021 · CA · contact PI
Role of novel onco-histone mutations in B-cell malignancies$664,854
R01 · FY2020 · CA · contact PI
Weill Cornell Initiative for Maximizing Student Development$517,954
R25 · FY2020 · GM · contact PI
(PQ 6) New Models of KSHV Oncogenesis and KS Immune Environment$416,939
R01 · FY2020 · CA · contact PI
Role of novel onco-histone mutations in B-cell malignancies$682,229
R01 · FY2019 · CA · contact PI
The 22nd International Conference on Kaposi's sarcoma-associated herpesvirus and Related Agents$8,000
R13 · FY2019 · CA · contact PI
Defining the Cellular Oncogenome of Kaposi Sarcoma$171,135
R21 · FY2018 · CA · contact PI
Defining the Cellular Oncogenome of Kaposi Sarcoma$223,324
R21 · FY2017 · CA · contact PI
Modeling KSHV latency in vivo$328,499
R01 · FY2016 · CA · contact PI
Targeting vFLIP for the treatment of KSHV-associated malignancies$350,675
R01 · FY2015 · CA · contact PI
Modeling KSHV latency in vivo$328,499
R01 · FY2015 · CA · contact PI
Targeting vFLIP for the treatment of KSHV-associated malignancies$340,155
R01 · FY2014 · CA · contact PI
Modeling KSHV latency in vivo$318,644
R01 · FY2014 · CA · contact PI
Immunology and Microbial Pathogenesis Research Training Program$205,454
T32 · FY2014 · AI · contact PI
Targeting vFLIP for the treatment of KSHV-associated malignancies$329,635
R01 · FY2013 · CA · contact PI
Modeling KSHV latency in vivo$308,788
R01 · FY2013 · CA · contact PI
Immunology and Microbial Pathogenesis Research Training Program$216,187
T32 · FY2013 · AI · contact PI
Targeting vFLIP for the treatment of KSHV-associated malignancies$350,675
R01 · FY2012 · CA · contact PI
Modeling KSHV latency in vivo$328,499
R01 · FY2012 · CA · contact PI
Immunology and Microbial Pathogenesis Research Training Program$160,814
T32 · FY2012 · AI · contact PI
Targeting vFLIP for the treatment of KSHV-associated malignancies$350,675
R01 · FY2011 · CA · contact PI
Immunology and Microbial Pathogenesis Research Training Program$173,490
T32 · FY2011 · AI · contact PI
Survival Signals in AIDS Lymphomas$281,837
R01 · FY2010 · CA · contact PI
Immunology and Microbial Pathogenesis Research Training Program$210,654
T32 · FY2010 · AI · contact PI
Survival Signals in AIDS Lymphomas$458,900
R01 · FY2009 · CA · contact PI
Survival Signals in AIDS Lymphomas$468,855
R01 · FY2008 · CA · contact PI
Immunology Research Training Program$346,549
T32 · FY2008 · AI · contact PI
KSHV vFLIP in B cell survival$326,554
R01 · FY2008 · CA · contact PI
KSHV vFLIP in B cell survival$494,554
R01 · FY2007 · CA · contact PI
Immunology Research Training Program$246,083
T32 · FY2007 · AI · contact PI
Identifying small molecule inhibitors of KSHV vFLIP-TRAF2 interactions.$157,927
R21 · FY2007 · CA · contact PI
KSHV vFLIP in B cell survival$336,307
R01 · FY2006 · CA · contact PI
Identifying small molecule inhibitors of KSHV vFLIP-TRAF2 interactions.$211,772
R21 · FY2006 · CA · contact PI
KSHV vFLIP in B cell survival$344,400
R01 · FY2005 · CA
KSHV/HHV 8 IN AIDS LYMPHOMAS$276,073
R01 · FY2005 · CA
KSHV vFLIP in B cell survival$344,400
R01 · FY2004 · CA
KSHV/HHV 8 IN AIDS LYMPHOMAS$276,073
R01 · FY2004 · CA
KSHV/HHV 8 IN AIDS LYMPHOMAS$276,073
R01 · FY2003 · CA
KSHV/HHV 8 IN AIDS LYMPHOMAS$276,073
R01 · FY2002 · CA
KSHV/HHV 8 IN AIDS LYMPHOMAS$276,073
R01 · FY2001 · CA
KSHV TRANSFORMATION AND ANGIOGENESIS IN KAPOSIS SARCOMA$243,988
R01 · FY2001 · CA
KSHV TRANSFORMATION AND ANGIOGENESIS IN KAPOSIS SARCOMA$236,882
R01 · FY2000 · CA